GlassScriptPhysician profile
Michelle E Ciccone
NPI 1497325385
$5,712.44
in general payments reported to CMS, 2019-2025
26 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $735 · 2022: $1,635 · 2023: $954 · 2024: $1,196 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,342 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,341.53 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $895.78 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $633.54 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $623.52 | 2021-2024 | Ultomiris, Soliris |
| E.R. Squibb & Sons, L.L.C. | $427.06 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $356.72 | 2021-2025 | Kisunla |
| Pfizer INC. | $342.83 | 2023-2025 | |
| Biogen, INC. | $266.77 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $215.43 | 2022 | |
| Eisai INC. | $204.94 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $200.10 | 2024-2025 | Wainua |
| Teva Pharmaceuticals USA, INC. | $187.35 | 2021-2022 | |
| Sk Life Science, INC. | $180.85 | 2023 | Xcopri |
| Ucb, INC. | $173.06 | 2024-2025 | Fintepla, Rystiggo, Nayzilam |
| Amgen INC. | $169.47 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $138.27 | 2022-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $113.98 | 2025 | |
| Genzyme Corporation | $106.32 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $92.42 | 2021 | |
| Celgene Corporation | $82.16 | 2023-2024 | Zeposia |
| Argenx US, INC. | $79.97 | 2022-2025 | Vyvgart |
| Impel Pharmaceuticals INC. | $70.22 | 2022 | |
| Jazz Pharmaceuticals INC. | $57.16 | 2025 | |
| Axsome Therapeutics, INC. | $37.45 | 2025 | Symbravo |
| Ani Pharmaceuticals, INC. | $25.07 | 2024 | Purified Cortrophin Gel |
| Amneal Pharmaceuticals LLC | $18.05 | 2022 | |
| Alkermes, INC. | $13.95 | 2023 | Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Ciccone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.